PT Soho Global Health Tbk, (SOHO) Fair Value & Analysis
Healthcare · ID · Market cap 15.2T IDR
Fair value as of: Jul 18, 2026
From 26 valuation models · updated 22 days ago
Share price −1.2% over the past month.
A solid business, but screening 19% overvalued on our models.
What matters now
- A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- Our model range runs from 748.80 IDR (bear) to 1,241 IDR (bull), base 969.59 IDR. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 70/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range 357.31 IDR – 3,291 IDR · fair‑value band 748.80 IDR – 1,241 IDR · the 1,200 IDR price screens above the 969.59 IDR fair value. Dashed = 300-day average. As of Jul 18, 2026.
Analysis
PT Soho Global Health Tbk, (SOHO) currently trades at 1,200 IDR, while our model-based Fair Value estimate is 969.59 IDR, implying the stock looks roughly 19.2% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, PT Soho Global Health Tbk, generated revenue of 10.7T IDR at a net margin of 6.1%. Revenue declined 1.3% year over year. It earns a return on equity of 23.4%. The balance sheet holds a net cash position of 1.1T IDR. Fundamentals as of Jul 18, 2026
Our scenario range runs from 748.80 IDR (bear case) to 1,241 IDR (bull case); at 1,200 IDR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 69% below its 52-week high and 107% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -19%, SOHO screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (1,371 IDR) versus Asset-Based (136.36 IDR). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Soho Global Health Tbk, together with its subsidiaires, operates as a healthcare company in Indonesia. It operates through Distributions, Consumer Health, Alliance, and Others segments.
Full company description
PT Soho Global Health Tbk, together with its subsidiaires, operates as a healthcare company in Indonesia. It operates through Distributions, Consumer Health, Alliance, and Others segments. The company researches, develops, and markets specialty-focused medicines for use in the therapeutic areas of immunomodulator, respiratory, inflammation, and liver diseases; offers nonprescription brand products to treat and prevent diseases; and distribution and logistics services. It also offers body defense, stamina and vitality, brain nutrient, eye health, skin care, weight management, and wellness products; sells and markets medical devices and medical equipment products in the areas of wound care, hospital general care, surgery, orthopedics, and in-vitro diagnostics; and provides product registration, marketing intelligence, sales, and marketing support services. In addition, it provides contract manufacturing services for various dosage forms. The company was founded in 1946 and is headquartered in Jakarta, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Soho Global Health Tbk, reported revenue of 10.8T IDR in FY2025 versus 7.1T IDR in FY2021, a compound +11.1%/yr. Reported net income was 600B IDR in FY2025, compounding +2.2%/yr from FY2021.
SOHO screens 19% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare PT Soho Global Health Tbk, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Soho Global Health Tbk, (SOHO) overvalued or undervalued?
What is the fair value of SOHO?
What is the quality score of SOHO?
What is the revenue of PT Soho Global Health Tbk, (SOHO)?
What is the net profit margin of SOHO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Soho Global Health Tbk, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.